SPPL3

Across TCGA pan-cancer cohorts, SPPL3 mass-spec protein is linked to patient survival in 3 of 34 cancer types, making it a survival-associated SPPL3 data layer compared with 19 for mass-spec protein and 6 for mutation status.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher SPPL3 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated SPPL3 expression acts as an unfavorable survival marker, although some lineages such as HNSC and LUAD show a favorable association.

HNSC, LUAD, and GBM are the cancer types where SPPL3 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	DFS	Median	All	1.000	0.499	.033	2	view →
LUAD	DFS	Tertile	II,III,IV	1.000	0.310	.040	2	view →
GBM	OS	Median	All	0.947	0.764	.043	1	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

SPPL3–HNSC (DFS)

Open the HNSC breakdown →